OBJECTIVE: To compare patching with atropine eyedrops in the treatment of moderate amblyopia (visual acuity, 20/40-20/100) in children aged 7 to 12 years. METHODS: In a randomized, multicenter clinical trial, 193 children with amblyopia were assigned to receive weekend atropine or patching of the sound eye 2 hours per day. Main Outcome Measure Masked assessment of visual acuity in the amblyopic eye using the electronic Early Treatment Diabetic Retinopathy Study testing protocol at 17 weeks. RESULTS: At 17 weeks, visual acuity had improved from baseline by an average of 7.6 letters in the atropine group and 8.6 letters in the patching group. The mean difference between groups (patching - atropine) adjusted for baseline acuity was 1.2 letters (ends of complementary 1-sided 95% confidence intervals for noninferiority, -0.7, 3.1 letters). This difference met the prespecified definition for equivalence (confidence interval <5 letters). Visual acuity in the amblyopic eye was 20/25 or better in 15 participants in the atropine group (17%) and 20 in the patching group (24%; difference, 7%; 95% confidence interval, -3% to 17%). CONCLUSIONS: Treatment with atropine or patching led to similar degrees of improvement among 7- to 12-year-olds with moderate amblyopia. About 1 in 5 achieved visual acuity of 20/25 or better in the amblyopic eye. CLINICAL RELEVANCE: Atropine and patching achieve similar results among older children with unilateral amblyopia. TRIAL REGISTRATION: (clinicaltrials.gov) Identifier: NCT00315328.
RCT Entities:
OBJECTIVE: To compare patching with atropine eyedrops in the treatment of moderate amblyopia (visual acuity, 20/40-20/100) in children aged 7 to 12 years. METHODS: In a randomized, multicenter clinical trial, 193 children with amblyopia were assigned to receive weekend atropine or patching of the sound eye 2 hours per day. Main Outcome Measure Masked assessment of visual acuity in the amblyopic eye using the electronic Early Treatment Diabetic Retinopathy Study testing protocol at 17 weeks. RESULTS: At 17 weeks, visual acuity had improved from baseline by an average of 7.6 letters in the atropine group and 8.6 letters in the patching group. The mean difference between groups (patching - atropine) adjusted for baseline acuity was 1.2 letters (ends of complementary 1-sided 95% confidence intervals for noninferiority, -0.7, 3.1 letters). This difference met the prespecified definition for equivalence (confidence interval <5 letters). Visual acuity in the amblyopic eye was 20/25 or better in 15 participants in the atropine group (17%) and 20 in the patching group (24%; difference, 7%; 95% confidence interval, -3% to 17%). CONCLUSIONS: Treatment with atropine or patching led to similar degrees of improvement among 7- to 12-year-olds with moderate amblyopia. About 1 in 5 achieved visual acuity of 20/25 or better in the amblyopic eye. CLINICAL RELEVANCE: Atropine and patching achieve similar results among older children with unilateral amblyopia. TRIAL REGISTRATION: (clinicaltrials.gov) Identifier: NCT00315328.
Authors: P S Moke; A H Turpin; R W Beck; J M Holmes; M X Repka; E E Birch; R W Hertle; R T Kraker; J M Miller; C A Johnson Journal: Am J Ophthalmol Date: 2001-12 Impact factor: 5.258
Authors: Mitchell M Scheiman; Richard W Hertle; Roy W Beck; Allison R Edwards; Eileen Birch; Susan A Cotter; Earl R Crouch; Oscar A Cruz; Bradley V Davitt; Sean Donahue; Jonathan M Holmes; Don W Lyon; Michael X Repka; Nicholas A Sala; David I Silbert; Donny W Suh; Susanna M Tamkins Journal: Arch Ophthalmol Date: 2005-04
Authors: S R Cole; R W Beck; P S Moke; M P Celano; C D Drews; M X Repka; J M Holmes; E E Birch; R T Kraker; K E Kip Journal: J AAPOS Date: 2001-08 Impact factor: 1.220
Authors: Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace Journal: Ophthalmology Date: 2004-11 Impact factor: 12.079
Authors: Roy W Beck; Pamela S Moke; Andrew H Turpin; Frederick L Ferris; John Paul SanGiovanni; Chris A Johnson; Eileen E Birch; Danielle L Chandler; Terry A Cox; R Clifford Blair; Raymond T Kraker Journal: Am J Ophthalmol Date: 2003-02 Impact factor: 5.258
Authors: Richard W Hertle; Mitchell M Scheiman; Roy W Beck; Danielle L Chandler; Darron A Bacal; Eileen Birch; Raymond H Chu; Jonathan M Holmes; Deborah L Klimek; Katherine A Lee; Michael X Repka; David R Weakley Journal: Arch Ophthalmol Date: 2007-05
Authors: Joost Felius; Danielle L Chandler; Jonathan M Holmes; Raymond H Chu; Stephen R Cole; Michael Hill; Kristine Huang; Marjean Taylor Kulp; Elizabeth L Lazar; Noelle S Matta; Michele Melia; David K Wallace Journal: J AAPOS Date: 2010-10 Impact factor: 1.220
Authors: Eileen E Birch; Reed M Jost; Angie De La Cruz; Krista R Kelly; Cynthia L Beauchamp; Lori Dao; David Stager; Joel N Leffler Journal: J AAPOS Date: 2019-05-16 Impact factor: 1.220